New learning discoveries about 25637-16-5

As the paragraph descriping shows that 25637-16-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.

Step 1: (5-Methyl-i ,2-oxazol-3-yl)(oxan-4-yl)methanol4-Bromooxane (270 jiL, 2.42 mmol) was added drop wise to a stirred suspension of magnesium (58.9 mg, 2.42 mmol) and one crystal of iodine in THF (1700 jiL) at ambient temperature. The reaction mixture was stirred for 1 h before 5-methyl-i ,2 – oxazole-3-carbaldehyde (119 jiL, i.28 mmol) was added in a single portion. The reaction mixture was then stirred for 16 h. The reaction mixture was quenched with a minimumamount of saturated aqueous ammonium chloride (5 mL), and the volatiles were removed under reduced pressure. The crude reaction material was purified using reverse phase preparatory HPLC (TFA/acetonitrile/water). (5-Methyl-i ,2 -oxazol-3 -yl)(oxan-4- yl)methanol (90.9 mg, 0.461 mmol, 36 %) was isolated as a colorless oil. LC/MS (M+H) = 198.2; LC/MS RT = 0.84 mm (Column: Phenomenex Luna 30 x 2.0 mm 3u; MobilePhase A: 10:90 acetonitrile:water with 0.1% TFA; Mobile Phase B: 90:10 acetonitrile:water with 0.1% TFA; Temperature: 40 C; Gradient: 0-100% B over 2 mm; Flow: 1 mL/min).

As the paragraph descriping shows that 25637-16-5 is playing an increasingly important role.

Reference£º
Patent; BRISTOL-MYERS SQUIBB COMPANY; NORRIS, Derek J.; DELUCCA, George V.; GAVAI, Ashvinikumar V.; QUESNELLE, Claude A.; GILL, Patrice; O’MALLEY, Daniel; VACCARO, Wayne; LEE, Francis Y.; DEBENEDETTO, Mikkel V.; DEGNAN, Andrew P.; FANG, Haiquan; HILL, Matthew D.; HUANG, Hong; SCHMITZ, William D.; STARRETT, JR, John E.; HAN, Wen-Ching; TOKARSKI, John S.; MANDAL, Sunil Kumar; WO2015/100282; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Some tips on 25637-16-5

25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25637-16-5,4-Bromotetrahydropyran,as a common compound, the synthetic route is as follows.

General procedure: To a solution of Compound 141C (300 mg, 0.71 mmol) in dry THF (10 mL) was dropped a solution of phenylmagnesium bromide in THF (1 M, 1 mL, 1.0 mmol) at -78 over 5 minutes. The mixture was stirred at -78 for 1 hour. The reaction mixture was poured into saturated aqueous ammonium chloride solution (50 mL) and extracted with ethyl acetate (50 mL x 3). The combined organic layers was washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified with flash column chromatography on silica gel (ethyl acetate in petroleum, 20% v/v) to furnish Compound 141. LC-MS (ESI) m/z: 501 [M+H]+;1H-NMR (CDCl3, 400 MHz): delta (ppm) , 4.45 (s, 1H), 7.33-7.40 (m, 9 H), 7.45 (m, 2H), 7.59-7.61 (m, 2H).To a mixture of magnesium (159 mg, 6.6 mmol) and a small amount of iodine in anhydrous THF (10 mL) were added 1,2-dibromomethane (0.1 mL) and heated at 50 C for 10 minutes. To the mixture was dropped a solution of Compound 174A (1 g, 4.4 mmol) in THF (2 mL) and stirred at 80 C for 2 hours. The resulting Grignard reagent 174B was cooled down to room temperature and used directly in the next step.Compound 174 was synthesized by employing the procedure described for Compound 141 using Grignard reagent 174B in lieu of phenylmagnesium bromide. LC-MS (ESI) m/z: 1163 [2M+Na]+;1H-NMR (CDCl3, 400 MHz): delta (ppm) 1.64-1.71 (m, 1H), 1.82- 1.90 (m, 1H), 2.10-2.19 (m, 2H), 2.39-2.46 (m, 2H), 4.58-4.64 (m, 1H), 6.77 (d, J = 8.4 Hz, 2H), 7.27-7.29 (m, 2H), 7.30-7.34 (m, 4H), 7.37-7.38 (m, 2H), 7.56 (d, J = 8.0 Hz, 2H).Compounds 207B and 207 were synthesized by employing the procedures described for Compounds 174B and 141 using Compounds 207A, 207B, and at -60 C in lieu of Compounds 174A, phenylmagnesium bromide, and -78 C.Compound 207B as a Grignard reagent solution, which was directly used in the next step. Compound 207. LC-MS (ESI) m/z: 509 [M+H]+;1H-NMR (DMSO-d6, 400 MHz): delta (ppm) 1.02-1.12 (m, 1H), 1.54-1.65 (m, 2H), 1.75-1.86 (m, 1H), 1.94-2.01 (m, 1H), 304-3.18 (m, 2H), 3.77-3.86 (m, 2H), 3.39 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.8 Hz, 2H), 7.68- 7.79 (m, 5H).

25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; BIOMARIN PHARMACEUTICAL INC.; WANG, Bing; (552 pag.)WO2017/214505; (2017); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Brief introduction of 14774-37-9

As the paragraph descriping shows that 14774-37-9 is playing an increasingly important role.

14774-37-9, Tetrahydropyran-4-methanol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

I: Toluene-4-sulfonic acid tetrahydropyran-4-ylmethyl ester intermediate p-Toluenesulfonyl chloride (29.8 g, 157 mmol) was added portionwise to a mixture of tetrahydro-2/-/-pyran-4-yl-methanol (20.0 g, 172 mmol) and pyridine (25.2 ml, 313 mmol) in dichloromethane (200 ml). The mixture was stirred at room temperature for 17 h, then quenched with aqueous hydrochloric acid (2 M; 100 ml). The layers were separated and the aqueous layer extracted with dichloromethane (2 x 100 ml). The organic layers were combined and concentrated in vacuo. Recrystallisation from dichloromethane: n-heptane (5:1 ) afforded toluene-4-sulfonic acid tetrahydro-pyran-4-ylmethyl ester. The mother liquors were further purified by silica gel column chromatography eluting with 50% dichloromethane in n-heptane to yield a further quantity of toluene-4-sulfonic acid tetrahydro-pyran-4-ylmethyl ester (total yield 41.6 g, 154 mmol).

As the paragraph descriping shows that 14774-37-9 is playing an increasingly important role.

Reference£º
Patent; AKZO NOBEL N.V.; WO2007/23143; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Some tips on 29943-42-8

As the paragraph descriping shows that 29943-42-8 is playing an increasingly important role.

29943-42-8, Dihydro-2H-pyran-4(3H)-one is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 75 g (0.75 mol) of Compound 22 in THF (150 mL) is added a suspension of 28.4 g (0.75 mol) LiAlH4 in THF (600 mL) under nitrogen atmosphere maintaining the temperature below 30 C. with the aid of an ice-bath. Then the reaction is allowed to warm to room temperature and stirred for 5 h. The reaction is quenched by addition of saturated aqueous NH4Cl solution until effervescence ceased. The resulting precipitate is removed by filtration through Celite and washed with THF (150 mL). The filtrate is concentrated under reduced pressure to afford 71.1 g of Compound 23 as a pale yellow oil. Yield: 92%, 1H NMR (500 MHz, CHLOROFORM-d) delta ppm 1.54 (2H, m), 1.81-1.92 (2H, m), 2.11 (1H, br. s.), 3.38-3.47 (2H, m), 3.83 (1H, tt, J=9.10, 4.38 Hz), 3.94 (2H, dt, J=11.88, 4.15 Hz).

As the paragraph descriping shows that 29943-42-8 is playing an increasingly important role.

Reference£º
Patent; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; US2011/71196; (2011); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Downstream synthetic route of 29943-42-8

29943-42-8 Dihydro-2H-pyran-4(3H)-one 121599, aTetrahydropyrans compound, is more and more widely used in various.

29943-42-8, Dihydro-2H-pyran-4(3H)-one is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of tetrahydro-pyran-4-one (1.3 kg, 12.98 mol) and carbonic acid dimethyl ester (11.69 kg, 129.8 mol) was added solid potassium ferf-butoxide (1.89 kg, 16.08 mol) in portions at -10C over 2 h under nitrogen protection. The suspension was stirred at room temperature 10 h after the addition. LCMS (215nm) indicated that tetrahydro-pyran-4-one had been completely consumed. The reaction was acidified by HCl (2 N) to pH 6~7 and then the phases were separated. The organic phase was washed with water (3 Lx2) and the combined aqueous phases were extracted with MTBE (2.5 Lx2). The combined organic phase was concentrated under reduced pressure at 25C to remove most of MTBE. The residue was distilled out by oil pump (~200 Pa) at 74 C to give the title compound as colorless oil (545 g, 26.3%). CHN analysis: calculated (results). C 53.16 (53.10), H 6.37 (6.245), N 0.00 (0.00).

29943-42-8 Dihydro-2H-pyran-4(3H)-one 121599, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; NOVARTIS AG; CHEUNG, Atwood, Kim; CHIN, Donoval, Noel; FAN, Jianmei; SHULTZ, Michael, David; TOMLINSON, Ronald, Charles; WO2013/10092; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Analyzing the synthesis route of 19752-84-2

#N/A

19752-84-2, Tetrahydro-2H-pyran-3-ol is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Tetrahydro-2H-pyran-3-ol (0.051 g, 0.499 mmol was taken into THF (1 mL) followed by the addition of 1M potassium butoxide in THF (0.5 mL, 0.5 mmol). The mixture was stirred for about 10 min, then (i?)- 2-(2-fluoropyridin-4-yl)-8-phenyl-7,8-dihydro-6H-pyrrolo[2′,r:2,3]imidazo[4,5-6]pyridine (0.055 g, 0.166 mmol, Preparation 84) in THF (1 mL) was added and the mixture was heated at about 120 C for about 20 min in a microwave. The reaction was cooled to rt, quenched with water and extracted with 100 mL EtOAc. The organics were collected, passed through a phase separator, concentrated under reduced pressure and the residue purified via silica gel chromatography eluting with 75-100% EtOAc/heptanes to afford the title compound (0.03 g, 45 %); LC/MS (Table 1, Method ab) Rt = 0.89 min; MS m/z: 413 (M+ H)+. (TNF IC50 = B).

#N/A

Reference£º
Patent; ABBVIE INC.; BREINLINGER, Eric, C.; COX, Phil, B.; DAANEN, Jerome; DIETRICH, Justin; DJURIC, Stevan; DOMBROWSKI, Amanda, W.; FRANK, Kristine, E.; FRIEDMAN, Michael, M.; GOMTSYAN, Arthur; LI, Huan-Qui; LONGENECKER, Kenton; OSUMA, Augustine; ROWLEY, Ann, Marie; SCHMIDT, Robert; VASUDEVAN, Anil; WILSON, Noel; (378 pag.)WO2016/168641; (2016); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

New learning discoveries about 33821-94-2

As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

A solution of (Z)-phenyl N’-cyano-N-(3,4-difluorophenyl)carbamimidate (17.69 g, 64.70 mmol), 2-(3-bromopropoxy)tetrahydro-2H-pyran (22.80 g, 17.10 mL, 97.10 mmol) and K2CO3 (17.90 g, 129.00 mmol) in DMF (200 mL) was heated overnight at 85C. The reaction mixture was concentrated in vacuo and the residue was purified by column chromatography (Hept:EtOAc 90: 10 to 50:50) to give 3-cyano-l-(3,4-difluorophenyl)-2-phenyl-l-(3- tetrahydropyran-2-yloxypropyl)isourea as a white solid (26.90 g, 49%). MS (ES+) m/z: 416.2 [M+H]+.

As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.

Reference£º
Patent; F. HOFFMANN-LA ROCHE AG; HOFFMANN-LA ROCHE INC.; BARTELS, Bjoern; JAKOB-ROETNE, Roland; LIMBERG, Anja; NEIDHART, Werner; RATNI, Hasane; REUTLINGER, Michael; SARIE, Jerome Charles; VASTAKAITE, Greta; (70 pag.)WO2018/60300; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

New learning discoveries about 101691-65-0

#N/A

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.101691-65-0,(Tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To tert-butyl 3-(5-chloro-2-fluoropyridin-4-yl)phenylcarbamate (270 mg, 0.837 mmol) in DMF (3 rriL) was added slowly sodium hydride (60 wt.% in mineral oil, 40.1 mg) at 0 C. The ice bath was removed and the crude mixture was stirred for 20 min at room temperature. To the crude mixture was added (tetrahydro-2H-pyran-4-yl)methyl 4-methylbenzenesulfonate (271 mg, 1.004 mmol) and stirring was continued at 40 C for 40 hrs. The reaction mixture was cooled to room temperature and diluted with EtOAc (150 mL). The mixture was washed saturated aqueous sodium bicarbonate solution (2x), water (2x) and brine (lx), dried with sodium sulfate, filtered off and concentrated under reduced pressure. The residue was purified by column chromatography [silica gel, 24 g, EtO Ac/heptane = 0/100 to 30/70] providing [3-(5-chloro-2- fluoro-pyridin-4-yl)-phenyl]-(tetrahydro-pyran-4-ylmethyl)-carbamic acid tert-butyl ester (205 mg). LCMS (m/z): 421.2 [M+H]+; Retention time = 1.19 min.

#N/A

Reference£º
Patent; NOVARTIS AG; ANTONIOS-MCCREA, William R.; BARSANTI, Paul A.; HU, Cheng; JIN, Xianming; MARTIN, Eric J.; PAN, Yue; PFISTER, Keith B.; SENDZIK, Martin; SUTTON, James; WAN, Lifeng; WO2012/66065; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Simple exploration of 2081-44-9

As the paragraph descriping shows that 2081-44-9 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2081-44-9,Tetrahydro-2H-pyran-4-ol,as a common compound, the synthetic route is as follows.

To a solution of tetrahydro-211-pyran-4-ol (5 g, 49.0 mmol) and triethylamine (5.94 g, 58.7 rnmol) in DCM (100 mL) was added mesyl chloride (16.8 g, 146.9 mmol) dropwise at 0 C under a nitrogen atmosphere. The mixture was stirred at room temperature for 5 h. Water (100 mL) was added and extracted with DCM (100 mL x 2). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give the titlecompound (4 g, 45%) as a yellow solid. 1fl NMR (400 MHz, CDC13) 6 4.85 – 4.81 (m 11-I),3.90-3.87 (m, 211), 3.52 – 3.46 (m, 211), 2.99 (s, 3H), 2.01 – 1.97 (in, 2H), 1.83 – 1.80 (m,2H).

As the paragraph descriping shows that 2081-44-9 is playing an increasingly important role.

Reference£º
Patent; GENENTECH, INC.; CONSTELLATION PHARMACEUTICALS, INC.; ROMERO, F. Anthony; MAGNUSON, Steven; PASTOR, Richard; TSUI, Vickie Hsiao-Wei; MURRAY, Jeremy; CRAWFORD, Terry; ALBRECHT, Brian, K.; COTE, Alexandre; TAYLOR, Alexander, M.; LAI, Kwong Wah; CHEN, Kevin, X.; BRONNER, Sarah; ADLER, Marc; EGEN, Jackson; LIAO, Jiangpeng; WANG, Fei; CYR, Patrick; ZHU, Bing-Yan; KAUDER, Steven; (0 pag.)WO2016/86200; (2016); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

Simple exploration of 25637-16-5

25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various.

25637-16-5, 4-Bromotetrahydropyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

10565] To 2.lh (18 mg, 0.047 mmol) was added DMF (Volume: 0.5 mE) and cesium carbonate (53.8 mg, 0.165 mmol). The reaction was stirred at room temperature for 5 minutes then 4-bromotetrahydro-2H-pyran (19.47 mg, 0.118 mmol) was added. The reaction was heated to 70 C. and stirred for 20 hours or until done by ECMS. The reaction was cooled, 0.5 ml of DMF was added, then filtered through a 0.45 nM in line filtet The DMF solution with the desired product 2.38a was used as is for the next step, assume quantitative yield. EC-MS (mlz): 466.5 [M+H], 0.79 mm.

25637-16-5 4-Bromotetrahydropyran 13349654, aTetrahydropyrans compound, is more and more widely used in various.

Reference£º
Patent; Novartis AG; FU, Jiping; HAN, Wooseok; KARUR, Subramanian; LU, Peichao; PFISTER, Keith Bruce; YOUNG, Joseph Michael; (97 pag.)US2018/312507; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics